Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pivicasiran in Metabolic Dysfunction Associated Steatohepatitis: NCT06024408 Clinical Landscape Report 2026
15 October 2026
NCT06024408 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Nebokitug in Metabolic Dysfunction Associated Steatohepatitis: NCT06025851 Clinical Landscape Report 2026
15 October 2026
NCT06025851 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Nebokitug in Metabolic Dysfunction Associated Steatohepatitis: NCT06037577 Clinical Landscape Report 2026
15 October 2026
NCT06037577 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Sodium Pyruvate in Cough: NCT06037408 Clinical Landscape Report 2026
15 October 2026
NCT06037408 clinical landscape for Cough: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nebokitug in Metabolic Dysfunction Associated Steatohepatitis: NCT06044467 Clinical Landscape Report 2026
15 October 2026
NCT06044467 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Efinopegdutide in Hepatic Insufficiency: NCT06052566 Clinical Landscape Report 2026
15 October 2026
NCT06052566 clinical landscape for Hepatic Insufficiency: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Utreloxastat in Amyotrophic Lateral Sclerosis: JPRN-jRCT2011230040 Clinical Landscape Report 2026
15 October 2026
JPRN-jRCT2011230040 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ipilimumab in Microsatellite instability-high colorectal cancer: NCT06047379 Clinical Landscape Report 2026
15 October 2026
NCT06047379 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Fam-trastuzumab deruxtecan-NXKI in Metastatic Malignant Neoplasm to the Leptomeninges: NCT06058988 Clinical Landscape Report 2026
15 October 2026
NCT06058988 clinical landscape for Metastatic Malignant Neoplasm to the Leptomeninges: endpoints, sponsor, phase, geography, readouts, asset context and deve…
9 min read
Sitagliptin in Metabolic Dysfunction Associated Steatohepatitis: NCT06054815 Clinical Landscape Report 2026
15 October 2026
NCT06054815 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Nogapendekin alfa inbakicept-pmln in Glioblastoma Multiforme: NCT06061809 Clinical Landscape Report 2026
15 October 2026
NCT06061809 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atezolizumab in Recurrent Glioblastoma: NCT06069726 Clinical Landscape Report 2026
15 October 2026
NCT06069726 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.